Open Label Study (Extension 001)to Evaluate Long Term Treatment Effect of the Safety, Tolerability and Efficacy of Intervenous ALPHA-1 ANTITRYPSIN (AAT) (Glasia) in Type 1 Diabetes Mellitus (Extension to KAMADA AAt 008, PHASE I/II Study)
Latest Information Update: 07 Nov 2021
At a glance
- Drugs Alpha 1-antitrypsin (Primary)
- Indications Type 1 diabetes mellitus
- Focus Adverse reactions
- 10 Jan 2017 Status changed from active, no longer recruiting to completed.
- 02 Feb 2015 Results published in a Kamada media release.
- 12 Sep 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.